SSA
BCLI

Schonfeld Strategic Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-827
Closed -$48K – 1942
2021
Q1 		$48K Sell
827
-473
-36% -$35.7K ﹤0.01% 1720
2020
Q4 		$88K Buy
+1,300
New +$177K ﹤0.01% 1464

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Schonfeld Strategic Advisors's BCLI Position: Q2 2021 in Review

Schonfeld Strategic Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2021, closing a stake of 827 shares — an estimated $48K sold.

Schonfeld Strategic Advisors first reported a position in BCLI in Q4 2020 and held it in 2 quarters. The position peaked at $88K in Q4 2020. 57 funds tracked by Wall St. Rank hold BCLI as of Q2 2021.

  • Schonfeld Strategic Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 827 BRAINSTORM CELL THERAPUTC shares in Q2 2021, an estimated $48K.
  • Schonfeld Strategic Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2020 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's BRAINSTORM CELL THERAPUTC position peaked at $88K in Q4 2020.
  • 57 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.